Meridian Bioscience/ US5895841014 /
2023-01-30 10:00:00 PM | Chg. - | Volume | Bid1:50:00 AM | Ask1:50:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
33.9700USD | - | 6.42 mill. Turnover: 176.77 mill. |
33.7000Bid Size: - | 33.9900Ask Size: - | 1.5 bill.USD | - | 35.02 |
Assets
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 30.5100 | 29.9950 | 30.5670 | 31.1200 | 43.2140 | ||||||
Intangible Assets | 26.7040 | 23.1130 | 60.2430 | 83.1970 | 84.1510 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | 115.9020 | 112.3240 | 180.7170 | 243.0710 | 256.9150 | ||||||
Inventories | 41.4930 | 41.9930 | 39.6170 | 61.2640 | 76.8420 | ||||||
Accounts Receivable | 29.1060 | 32.3360 | 35.6080 | 38.5120 | 53.5680 | ||||||
Cash and Cash Equivalents | 57.0720 | 59.7630 | 62.3970 | 53.5140 | 49.7710 | ||||||
Current Assets | 133.8750 | 139.0530 | 144.7610 | 162.1900 | 192.8070 | ||||||
Total Assets | 249.7770 | 251.3770 | 325.4780 | 405.2610 | 449.7220 |
Liabilities
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 7.7190 | 6.2600 | 7.2380 | 11.9690 | 11.7010 | ||||||
Long-term debt | 50.1470 | 44.9300 | 75.8240 | 68.8240 | 60 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | 4.5000 | 3.8000 | 2.5000 | 3.8000 | - | ||||||
Liabilities | 80.1920 | 75.9590 | 134.5110 | 157.6320 | 121.4200 | ||||||
Share Capital | - | - | - | - | - | ||||||
Total Equity | 169.5850 | 175.4180 | 190.9670 | 247.6290 | 328.3020 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 249.7770 | 251.3770 | 325.4780 | 405.2610 | 449.7220 |
Income Statement
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 200.7710 | 213.5710 | 201.0140 | 253.6670 | 317.8960 | ||||||
Depreciation (total) | 8.1180 | 7.9240 | 9.9640 | 13.5670 | 15.2860 | ||||||
Operating Result | 37.3820 | 31.5840 | 32.6990 | 61.3240 | 93.0340 | ||||||
Interest Income | -1.4710 | -1.1020 | -1.2640 | -2.4900 | -1.8780 | ||||||
Income Before Taxes | 36.4290 | 30.3800 | 31.5570 | 59.2930 | 90.4510 | ||||||
Income Taxes | 14.8720 | 6.5310 | 7.1750 | 13.1070 | 19.0440 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 21.5570 | 23.8490 | 24.3820 | 46.1860 | 71.4070 |
Per Share
Cash Flow
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 41.3550 | 34.7830 | 35.8310 | 47.9760 | 66.8650 | ||||||
Cash Flow from Investing Activities | -4.4670 | -4.2010 | -48.4520 | -54.5980 | -40.3970 | ||||||
Cash Flow from Financing | -27.7130 | -27.5930 | 15.2600 | -3.5570 | -31.0690 | ||||||
Decrease / Increase in Cash | 9.8460 | 2.6910 | 1.6340 | -8.8830 | -3.7430 | ||||||
Employees | 420 | 400 | 485 | 560 | - |